Natural history of bone metastasis in colorectal cancer: Final results of a large Italian bone metastases study

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2072-2077

  Santini, D ^a   Tampellini, M ^b   Vincenzi, B ^a   Ibrahim, T ^c   Ortega, C ^d   Virzi, V ^a   Silvestris, N ^e   Berardi, R ^f   Masini, C ^g   Calipari, N ^h   Ottaviani, D ⁱ   Catalano, V ^j   Badalamenti, G ^k   Giannicola, R ^h   Fabbri, F ^c   Venditti, O ^a   Fratto, M E ^a   Mazzara, C ^a   Latiano, T P ^l   Bertolini, F ^g   Petrelli, F ^m   Ottone, A ^b   Caroti, C ⁿ   Salvatore, L ^o   Falcone, A ^o   Giordani, P ^j   Addeo, R ^p   Aglietta, M ^b,d   Cascinu, S ^f   Barni, S ^m   Maiello, E ^l   Tonini, G ^a   more..

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

^c DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^d CANDIOLO CANCER INSTITUTE   (Italy)

^e NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^f UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^g University Hospital   (Italy)

^h BIANCHI MELACRINO MORELLI HOSPITAL   (Italy)

ⁱ GRADENIGO HOSPITAL   (Italy)

^j AO Ospedali Riuniti Marche Nord   (Italy)

^k UNIVERSITY OF PALERMO   (Italy)

^l CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^m TREVIGLIO HOSPITAL   (Italy)

ⁿ GALLIERA HOSPITAL   (Italy)

^o UNIVERSITY OF PISA   (Italy)

^p SAN GIOVANNI DI DIO HOSPITAL   (Italy)

more..

Author keywords

Bone metastases; Colorectal cancer; Zoledronic acid

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; ZOLEDRONIC ACID;

ARTICLE; BONE METASTASIS; COLORECTAL CANCER; HIP; HUMAN; HYPERCALCEMIA; ITALY; LONG BONE; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; ORTHOPEDIC SURGERY; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; PELVIS; PRIORITY JOURNAL; RADIOTHERAPY; RETROSPECTIVE STUDY; SPINAL CORD COMPRESSION; SPINE;

EID: 84864949554     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr572     Document Type: Article

References (34)

1. Ferlay J, Shin HR, Bray F et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893-2917.
2. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
3. Katoh M, Unakami M, Hara M, Fukuchi S. Bone metastasis from colorectal cancer in autopsy cases. J Gastroenterol 1995; 30: 615-618.
4. Roth ES, Fetzer DT, Barron BJ et al. Does colon cancer ever metastasize to bone first? a temporal analysis of colorectal cancer progression. BMC Cancer 2009; 9: 274.
5. Douillard JY, Siena S, Cassidy J et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705.
6. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
7. Saltz LB, Clarke S, Diaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
8. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237.
9. Van Cutsem E, Kohne CH, Hitre E et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360: 1408-1417.
10. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
11. Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-1594.
12. Choi SJ, Kim JH, Lee MR et al. Long-term disease-free survival after surgical resection for multiple bone metastases from rectal cancer. World J Clin Oncol 2011; 2: 326-328.
13. Heras P, Karagiannis S, Kritikos K et al. Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer. Eur J Cancer Care (Engl) 2007; 16: 539-542.
14. Nozue M, Oshiro Y, Kurata M et al. Treatment and prognosis in colorectal cancer patients with bone metastasis. Oncol Rep 2002; 9: 109-112.
15. Sebag-Montefiore DJ, Lam KS, Arnott SJ. Tarsal metastases in a patient with rectal cancer. Br J Radiol 1997; 70: 862-864.
16. Sundermeyer ML, Meropol NJ, Rogatko A et al. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer 2005; 5: 108-113.
17. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
18. Peto R, Pike MC, Armitage P et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer 1977; 35: 1-39.
19. Goldberg RM, Rothenberg ML, Van Cutsem E et al. The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist 2007; 12: 38-50.
20. Rosen LS, Gordon D, Kaminski M et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001; 7: 377-387.
21. Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormonerefractory prostate cancer. J Natl Cancer Inst 2004; 96: 879-882.
22. Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, doubleblind, placebo-controlled trial. Cancer 2004; 100: 2613-2621.
23. Rennert G, Pinchev M, Rennert HS, Gruber SB. Use of bisphosphonates and reduced risk of colorectal cancer. J Clin Oncol 2011; 29: 1146-1150.
24. Aviles A, Nambo MJ, Neri N et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma. Med Oncol 2007; 24: 227-230.
25. Body JJ, Cook R, Costa L et al. Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumors and poor prognostic features. Presented at the IX International Meeting on Cancer Induced Bone Disease, October 28-31, 2009. Arlington, VA. Poster 71.
26. Michaelson D, Kpamegan EE, Perez JR, Brown JE. Zoledronic acid (ZOL) reduces the incidence of skeletal-related events (SREs) and may improve survival in patients with bone metastases from renal cell carcinoma (RCC): a retrospective integrated analysis. Presented at 35th European Society for Medical Oncology (ESMO) Congress, 8-12 October, 2010 (Abstr 917P). Milan, Italy.
27. Morgan GJ, Davies FE, Gregory WM et al. First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010; 376: 1989-1999.
28. Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 1458-1468.
29. Zaghloul MS, Boutrus R, El-Hossieny H et al. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol 2010; 15: 382-389.
30. Zarogoulidis K, Boutsikou E, Zarogoulidis P et al. The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis. Int J Cancer 2009; 125: 1705-1709.
31. Aapro M, Abrahamsson PA, Body JJ et al. Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel. Ann Oncol 2008; 19: 420-432.
32. De Marinis F, Eberhardt W, Harper PG et al. Bisphosphonate use in patients with lung cancer and bone metastases: recommendations of a European expert panel. J Thorac Oncol 2009; 4: 1280-1288.
33. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057.
34. Van Poznak CH, Temin S, Yee GC et al. American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 2011; 29: 1221-1227.